The first edition of the European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) in adults, published in 2010, has found …

FLT3 is the most frequently mutated gene in acute myeloid leukemia (AML), with FLT3
internal tandem duplication (ITD) mutations being associated with a more aggressive clinical …

The prognosis of adult acute myeloid leukemia (AML) remains poor, with the long-term
survival rate less than 50%. However, the current paradigms of treatment are changing …

PURPOSE Magrolimab is a first-in-class humanized monoclonal antibody against cluster of
differentiation 47, an antiphagocytic signal used by cancer cells to evade phagocytosis …

Cancer incidence and mortality are rapidly growing worldwide. In attempts to develop more
efficacious therapeutic regimens for patients with cancer, nanomedicines have found …

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy in terms of
clinical features, underlying pathogenesis and treatment outcomes. Recent advances in …

We describe genetic and clinical characteristics of acute myeloid leukemia (AML) patients
according to age from an academic population-based registry. Adult patients with newly …

Abstract The European LeukemiaNet (ELN) recommendations for diagnosis and
management of acute myeloid leukemia (AML) have become an important tool to assess …

Older patients with newly diagnosed acute myeloid leukemia (AML) in the phase 3 AZA-AML-
001 study were evaluated at entry for cytogenetic abnormalities, and a subgroup of patients …

The outcome of acute myeloid leukemia patients aged 70 years or older is poor. Defining the
best treatment option remains controversial especially when choosing between intensive …